Tuesday, November 17, 2026
Newsletter About
Business & Finance

The FDA declined to approve one of biotech’s most closely watched cancer drugs. The company’s stock tumbled.

The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.

This article was originally published by MarketWatch and is republished here under license.

The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.

More in Business & Finance

View All →

Leave a Reply